A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

Table 4 Microbiologic response at the patient level (ME Population) at test-of-cure visit

	Tigecycline		Imipenem/cilastatin		Difference Tigecycline-Imipenem/cilastatin	Test for Noninferiority	Test for Differences
Response	N	% (95% CI)	N	% (95% CI)	% (95% CI)	P value
Eradication	199/247	80.6 (75.1, 85.3)	210/255	82.4 (77.1, 86.8)	-1.8 (-9.0, 5.4)	0.0001	0.6892
Persistence	39/247	15.8 (11.5, 20.9)	42/255	16.5 (12.1, 21.6)
Documented	4/39	10.3 (2.9, 24.2)	1/42	2.4 (0.1, 12.6)
Presumed	35/39	89.7 (75.8, 97.1)	41/42	97.6 (87.4, 99.9)
Superinfection	9/247	3.6 (1.7, 6.8)	3/255	1.2 (0.2, 3.4)
Overall					-1.7 (-8.4, 5.1)*

*Adjusted difference and its 95%CI are calculated from a generalized linear model with a binomial probability function and an identity link.

ISSN: 1471-2334